These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26488531)

  • 21. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis.
    Cooper N; Rao K; Gilmour K; Hadad L; Adams S; Cale C; Davies G; Webb D; Veys P; Amrolia P
    Blood; 2006 Feb; 107(3):1233-6. PubMed ID: 16219800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients.
    Waki F; Masuoka K; Fukuda T; Kanda Y; Nakamae M; Yakushijin K; Togami K; Nishiwaki K; Ueda Y; Kawano F; Kasai M; Nagafuji K; Hagihara M; Hatanaka K; Taniwaki M; Maeda Y; Shirafuji N; Mori T; Utsunomiya A; Eto T; Nakagawa H; Murata M; Uchida T; Iida H; Yakushiji K; Yamashita T; Wake A; Takahashi S; Takaue Y; Taniguchi S
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):841-51. PubMed ID: 20849969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.
    Gonzalez-Llano O; Jaime-Pérez J; Cantu-Rodríguez O; Mancias-Guerra C; Gutierrez-Aguirre H; Herrera-Garza J; Gomez-Almaguer D
    Eur J Haematol; 2006 Oct; 77(4):341-4. PubMed ID: 16856932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
    Rzepecki P; Sarosiek T; Szczylik C
    Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation.
    Jabbour E; Rondon G; Anderlini P; Giralt SA; Couriel DR; Champlin RE; Khouri IF
    Bone Marrow Transplant; 2007 Sep; 40(5):431-5. PubMed ID: 17603511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early identification and management of graft failure after unrelated cord blood transplantation.
    Chan KW; Grimley MS; Taylor C; Wall DA
    Bone Marrow Transplant; 2008 Jul; 42(1):35-41. PubMed ID: 18332909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
    Ahmed N; Leung KS; Rosenblatt H; Bollard CM; Gottschalk S; Myers GD; Carrum G; Heslop HE; Brenner MK; Krance RA
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1298-304. PubMed ID: 18940685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
    Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin.
    Rowley SD; Goldberg SL; Pecora AL; Hsu JS; Brecher BA; Butrin L; Kobbe K; McKiernan P; Preti R
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):784-93. PubMed ID: 15505609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
    Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C
    Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced intensity conditioning regimen with fludarabine, cyclophosphamide, low dose TBI and alemtuzumab leading to successful unrelated umbilical cord stem cell engraftment and survival in two children with dyskeratosis congenita.
    Brown M; Myers D; Shreve N; Rahmetullah R; Radhi M
    Bone Marrow Transplant; 2016 May; 51(5):744-6. PubMed ID: 26808569
    [No Abstract]   [Full Text] [Related]  

  • 33. Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation.
    Tomonari A; Takahashi S; Ooi J; Nakaoka T; Takasugi K; Uchiyama M; Tsukada N; Konuma T; Iseki T; Tojo A; Asano S
    Eur J Haematol; 2006 Jul; 77(1):46-50. PubMed ID: 16573743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conditioning with purine analogs leads to good engraftment rates of immunodepleted grafts for aplastic anemia.
    Novitzky N; Thomas V; du Toit C
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):584-8. PubMed ID: 23270985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis.
    Takagi S; Ota Y; Uchida N; Takahashi K; Ishiwata K; Tsuji M; Yamamoto H; Asano-Mori Y; Matsuno N; Masuoka K; Wake A; Miyakoshi S; Ohashi K; Taniguchi S
    Blood; 2010 Jul; 116(4):649-52. PubMed ID: 20439618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
    Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
    Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.
    Straathof KC; Rao K; Eyrich M; Hale G; Bird P; Berrie E; Brown L; Adams S; Schlegel PG; Goulden N; Gaspar HB; Gennery AR; Landais P; Davies EG; Brenner MK; Veys PA; Amrolia PJ
    Lancet; 2009 Sep; 374(9693):912-20. PubMed ID: 19729196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.